Latest news and press releases about Protagenic Therapeutics, Inc. (PTIX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.
Price
| Price | $0.84 |
| Market Cap | $2M |
| Exchange | OTC |
| Country | US |
Valuation Ratios
| P/E Ratio | 0.28 |
| Price / Book | 0.88 |
| EV / EBITDA | -0.35 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -794.18% |
| Return on Invested Capital | -419.98% |
| Return on Assets | 261.82% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARTL · CARM · GTBP · INDP · LIPO · PBM · REVB
Explore sector: Healthcare · Biotechnology
More sections of PTIX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks